MCID: UTR033
MIFTS: 47

Uterine Corpus Cancer

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Uterine Corpus Cancer

MalaCards integrated aliases for Uterine Corpus Cancer:

Name: Uterine Corpus Cancer 12 15 17 74
Malignant Uterine Corpus Neoplasm 74
Corpus Uteri Cancer 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9460
ICD9CM 36 182
NCIt 51 C3556
SNOMED-CT 69 93718007
ICD10 34 C54 C54.9

Summaries for Uterine Corpus Cancer

Disease Ontology : 12 A uterine cancer that is located in the uterine corpus.

MalaCards based summary : Uterine Corpus Cancer, also known as malignant uterine corpus neoplasm, is related to uterine body mixed cancer and endometrial cancer. An important gene associated with Uterine Corpus Cancer is TP53 (Tumor Protein P53), and among its related pathways/superpathways are TGF-Beta Pathway and Endometrial cancer. The drugs Cisplatin and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include testes, ovary and endothelial, and related phenotypes are Decreased CDKN1A mRNA expression and Decreased CDKN1A mRNA expression

Related Diseases for Uterine Corpus Cancer

Diseases related to Uterine Corpus Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 99)
# Related Disease Score Top Affiliating Genes
1 uterine body mixed cancer 31.5 ERBB2 FBXW7 PIK3CA PPP2R1A TP53
2 endometrial cancer 31.3 BRCA1 ERBB2 MYC PIK3CA S100A6 TP53
3 uterine corpus serous adenocarcinoma 31.1 BRCA1 ERBB2 FBXW7 PIK3CA PPP2R1A TP53
4 uterine corpus endometrial carcinoma 11.2
5 adenomyoma of uterine corpus 11.2
6 uterine corpus sarcoma 11.2
7 mixed endometrial stromal and smooth muscle tumor 11.2
8 gastric papillary adenocarcinoma 10.4 ERBB2 TP53
9 vulva basal cell carcinoma 10.4 ERBB2 MYC
10 pleomorphic adenoma carcinoma 10.4 ERBB2 TP53
11 non-proliferative fibrocystic change of the breast 10.4 ERBB2 TP53
12 b cell prolymphocytic leukemia 10.3 MYC TP53
13 megaesophagus 10.3 MYC TP53
14 glioma susceptibility 1 10.3 ERBB2 TP53
15 adult hepatocellular carcinoma 10.3 PIK3CA TP53
16 rare adenocarcinoma of the breast 10.3 PIK3CA TP53
17 microglandular adenosis 10.3 ERBB2 TP53
18 malignant spiradenoma 10.3 PIK3CA TP53
19 hypertrichosis universalis congenita, ambras type 10.3 MYC TP53
20 esophagus adenocarcinoma 10.3 ERBB2 TP53
21 suppressor of tumorigenicity 3 10.3 MYC TP53
22 prostate squamous cell carcinoma 10.3 PPP2R1A TP53
23 tuberculous salpingitis 10.3 BRCA1 ERBB2
24 myasthenic syndrome, congenital, 14 10.3 MYC PIK3CA
25 breast medullary carcinoma 10.3 BRCA1 ERBB2
26 synchronous bilateral breast carcinoma 10.3 BRCA1 TP53
27 fallopian tube adenocarcinoma 10.2 BRCA1 ERBB2
28 breast benign neoplasm 10.2 ERBB2 TP53
29 papillary serous adenocarcinoma 10.2 BRCA1 TP53
30 hemimegalencephaly 10.2 MYC PIK3CA
31 thoracic benign neoplasm 10.2 ERBB2 TP53
32 glycogen-rich clear cell breast carcinoma 10.2 BRCA1 TP53
33 papillary hidradenoma 10.2 PIK3CA S100A6
34 mixed cell type cancer 10.2 ERBB2 PPP2R1A TP53
35 carcinosarcoma 10.2 ERBB2 PIK3CA TP53
36 acneiform dermatitis 10.2 ERBB2 PIK3CA
37 breast squamous cell carcinoma 10.2 ERBB2 PIK3CA TP53
38 gastrointestinal system disease 10.2 ERBB2 MYC TP53
39 ovary adenocarcinoma 10.2 ERBB2 PIK3CA TP53
40 richter's syndrome 10.2 MYC TP53
41 estrogen-receptor positive breast cancer 10.2 ERBB2 PIK3CA TP53
42 uterine anomalies 10.2 ERBB2 PIK3CA TP53
43 lobular neoplasia 10.2 BRCA1 ERBB2
44 renal cell carcinoma, papillary, 1 10.2 ERBB2 PIK3CA TP53
45 oral cavity cancer 10.2 ERBB2 PIK3CA TP53
46 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 10.2 PIK3CA PPP2R1A TP53
47 intestinal disease 10.2 MYC PIK3CA TP53
48 ovarian clear cell carcinoma 10.2 PIK3CA PPP2R1A TP53
49 primary peritoneal carcinoma 10.1 BRCA1 ERBB2 TP53
50 pre-malignant neoplasm 10.1 BRCA1 ERBB2 TP53

Graphical network of the top 20 diseases related to Uterine Corpus Cancer:



Diseases related to Uterine Corpus Cancer

Symptoms & Phenotypes for Uterine Corpus Cancer

GenomeRNAi Phenotypes related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased CDKN1A mRNA expression GR00389-S-1 9.13 FBXW7 TP53
2 Decreased CDKN1A mRNA expression GR00389-S-2 9.13 TP53
3 Increased cell death HMECs cells GR00103-A-0 9.1 BRCA1 FBXW7 MYC PIK3CA PPP2R1A TP53

MGI Mouse Phenotypes related to Uterine Corpus Cancer:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 embryo MP:0005380 9.73 BRCA1 ERBB2 FBXW7 MYC PIK3CA TP53
2 endocrine/exocrine gland MP:0005379 9.7 BRCA1 ERBB2 FBXW7 MYC PIK3CA S100A6
3 integument MP:0010771 9.43 BRCA1 ERBB2 FBXW7 MYC PIK3CA TP53
4 neoplasm MP:0002006 9.17 BRCA1 ERBB2 FBXW7 MYC PIK3CA PPP2R1A

Drugs & Therapeutics for Uterine Corpus Cancer

Drugs for Uterine Corpus Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 127)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
2
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
3
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
4
Lenograstim Approved, Investigational Phase 3,Phase 1 135968-09-1
5
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
6
Doxorubicin Approved, Investigational Phase 3,Phase 1 23214-92-8 31703
7
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
8
Pembrolizumab Approved Phase 3 1374853-91-4
9
Doxil Approved June 1999 Phase 3,Phase 1 31703
10 Antimitotic Agents Phase 3,Phase 2,Phase 1
11 Topoisomerase Inhibitors Phase 3,Phase 1
12 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
13 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
14 Adjuvants, Immunologic Phase 3,Phase 1
15 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
16 Immunologic Factors Phase 3,Phase 2,Phase 1
17 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
18 Antineoplastic Agents, Immunological Phase 3,Phase 2
19 Hypoglycemic Agents Phase 2, Phase 3
20
Megestrol acetate Approved, Investigational, Vet_approved Phase 2 595-33-5 11683
21
Everolimus Approved Phase 2,Phase 1 159351-69-6 70789204 6442177
22
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 5284616 6436030
23
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
24
Tamoxifen Approved Phase 2 10540-29-1 2733526
25
Sodium Citrate Approved, Investigational Phase 2 68-04-2
26
Bevacizumab Approved, Investigational Phase 2 216974-75-3
27
Medroxyprogesterone acetate Approved, Investigational Phase 2 71-58-9
28
Dasatinib Approved, Investigational Phase 2,Phase 1 302962-49-8 3062316
29
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
30
nivolumab Approved Phase 2 946414-94-4
31
Olaparib Approved Phase 2 763113-22-0 23725625
32
Bupropion Approved Phase 2 34841-39-9, 34911-55-2 444
33
Dopamine Approved Phase 2 62-31-7, 51-61-6 681
34
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
35
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
36
Pertuzumab Approved Phase 2 380610-27-5, 145040-37-5 2540
37
Adenosine Approved, Investigational Phase 2 58-61-7 60961
38
Trametinib Approved Phase 2 871700-17-3 11707110
39
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
40
Palbociclib Approved, Investigational Phase 2 571190-30-2 5005498 11431660 5330286
41
Osimertinib Approved Phase 2 1421373-65-0 71496458
42
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760 44516822
43
Racepinephrine Approved Phase 2 329-65-7 838
44
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
45
afatinib Approved Phase 2 850140-72-6, 439081-18-2 10184653
46
Fulvestrant Approved, Investigational Phase 2 129453-61-8 17756771 104741
47
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
48
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
49
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
50
Maleic acid Experimental, Investigational Phase 2 110-17-8, 110-16-7 444972

Interventional clinical trials:

(show top 50) (show all 54)
# Name Status NCT ID Phase Drugs
1 Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Unknown status NCT00063999 Phase 3 Carboplatin;Cisplatin;Doxorubicin Hydrochloride;Paclitaxel
2 Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus Completed NCT00002706 Phase 3
3 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
4 Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
5 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
6 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
7 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
8 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
9 Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer Not yet recruiting NCT03914612 Phase 3 Carboplatin;Paclitaxel
10 Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cancer, or Endometrial Cancer Terminated NCT00577317 Phase 3
11 Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer Unknown status NCT02112552 Phase 2 Paclitaxel;Carboplatin
12 Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer Unknown status NCT01041027 Phase 2 Paclitaxel;Carboplatin
13 Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer Completed NCT00729586 Phase 2 Megestrol Acetate;Tamoxifen Citrate;Temsirolimus
14 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
15 Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus Completed NCT00064025 Phase 2 Medroxyprogesterone
16 Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer Completed NCT01005329 Phase 2 Carboplatin;Cisplatin;Paclitaxel
17 Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer Recruiting NCT02874430 Phase 2 Metformin Hydrochloride;Doxycycline
18 Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent or Metastatic Endometrial Cancer Recruiting NCT03367741 Phase 2 Cabozantinib;Cabozantinib S-malate
19 Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer Recruiting NCT02684227 Phase 2 Carboplatin;Enzalutamide;Paclitaxel
20 Health and Recovery Program in Increasing Physical Activity Level in Stage IA-IIIA Endometrial Cancer Survivors Recruiting NCT03367923 Phase 2
21 Olaparib and Cediranib Maleate in Treating Patients With Recurrent, Refractory, or Metastatic Endometrial Cancer Recruiting NCT03660826 Phase 2 Cediranib Maleate;Olaparib
22 Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer Recruiting NCT03180294 Phase 2 Bupropion Hydrochloride
23 Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Recruiting NCT02465060 Phase 2 Adavosertib;Afatinib;Binimetinib;Capivasertib;Copanlisib;Crizotinib;Dabrafenib;Dasatinib;Defactinib;Erdafitinib;FGFR Inhibitor AZD4547;Larotrectinib;Osimertinib;Palbociclib;PI3K-beta Inhibitor GSK2636771;Sapanisertib;Sunitinib Malate;Taselisib;Trametinib;Vismodegib
24 Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer Active, not recruiting NCT00006903 Phase 2 Fulvestrant
25 Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Active, not recruiting NCT00977574 Phase 2 Carboplatin;Ixabepilone;Paclitaxel;Temsirolimus
26 Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT01935934 Phase 2 Cabozantinib S-malate
27 Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT00478426 Phase 2 Sunitinib Malate
28 Megestrol in Treating Patients With Endometrial Neoplasia or Endometrial Hyperplasia Terminated NCT00503581 Phase 2 Megestrol Acetate
29 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00005840 Phase 1 Paclitaxel;Cisplatin
30 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00005830 Phase 1 Doxorubicin Hydrochloride;Cisplatin
31 Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors Completed NCT01522820 Phase 1 Sirolimus
32 Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer Completed NCT00575952 Phase 1 Cisplatin;Doxorubicin Hydrochloride;Paclitaxel
33 Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Completed NCT01440998 Phase 1 Carboplatin;Dasatinib;Paclitaxel
34 Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery Completed NCT00410553 Phase 1 Eribulin Mesylate;Gemcitabine Hydrochloride
35 Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer Recruiting NCT01970722 Phase 1 cisplatin;carboplatin;paclitaxel;pegylated liposomal doxorubicin hydrochloride;gemcitabine hydrochloride
36 Adavosertib, External Beam Radiation Therapy, and Cisplatin in Treating Patients With Cervical, Vaginal, or Uterine Cancer Recruiting NCT03345784 Phase 1 Adavosertib;Cisplatin
37 VSV-hIFNbeta-NIS in Treating Patients With Stage IV or Recurrent Endometrial Cancer Suspended NCT03120624 Phase 1 Technetium Tc-99m Sodium Pertechnetate
38 Physical Activity Behavioral Intervention in Obese Endometrial Cancer Survivors Unknown status NCT02575872 Not Applicable
39 Lymphedema After Surgery in Patients With Endometrial Cancer, Cervical Cancer, or Vulvar Cancer Unknown status NCT00956670 Not Applicable
40 Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malignancies Unknown status NCT02578888 Not Applicable
41 Weight Loss Referral for Healthier Survivorship in Obese Stage I-II Endometrial Cancer Survivors or Atypical Hyperplasia Completed NCT02342730 Not Applicable
42 Prognostic Biomarkers in Patients With Endometrial Cancer Completed NCT01208467
43 Collecting Tumor Samples From Patients With Gynecological Tumors Completed NCT00897442
44 Carevive Survivor Care Planning System in Improving Quality of Life in Breast Cancer Survivors Completed NCT03198286 Not Applicable
45 Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer Completed NCT01098630
46 Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer Recruiting NCT03042897 Not Applicable
47 Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery Active, not recruiting NCT02315469
48 Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Not yet recruiting NCT01164735
49 Racial and Genetic Biomarkers of Response in Tissue Samples From Patients With Endometrial Cancer Not yet recruiting NCT01198171
50 Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer Not yet recruiting NCT01344837

Search NIH Clinical Center for Uterine Corpus Cancer

Genetic Tests for Uterine Corpus Cancer

Anatomical Context for Uterine Corpus Cancer

MalaCards organs/tissues related to Uterine Corpus Cancer:

42
Testes, Ovary, Endothelial, Uterus, Lymph Node, Pancreas, Smooth Muscle

The Foundational Model of Anatomy Ontology organs/tissues related to Uterine Corpus Cancer:

20
The Uterine Corpus

Publications for Uterine Corpus Cancer

Articles related to Uterine Corpus Cancer:

(show all 30)
# Title Authors Year
1
Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement. ( 27894165 )
2017
2
Incidence and lifetime risk of uterine corpus cancer in Taiwanese women from 1991 to 2010. ( 28254229 )
2017
3
Laparoscopic Repair of Vaginal Evisceration after Abdominal Hysterectomy for Uterine Corpus Cancer: A Case Report and Literature Review. ( 28502966 )
2017
4
Reply to "Need for an up to date and comprehensive risk factor analysis to determine the lifetime risk of uterine corpus cancer in Taiwan women". ( 28805626 )
2017
5
Need for an up to date and comprehensive risk factor analysis to determine the lifetime risk of uterine corpus cancer in Taiwan women. ( 28805629 )
2017
6
Gemella morbillorum bacteremia following total laparoscopic hysterectomy for uterine corpus cancer. ( 30254882 )
2017
7
Lymphovascular space invasion in uterine corpus cancer: What is its prognostic significance in the absence of lymph node metastases? ( 27261326 )
2016
8
A prediction model of survival for patients with bone metastasis from uterine corpus cancer. ( 27655906 )
2016
9
Genitofemoral neuropathy after pelvic lymphadenectomy in patients with uterine corpus cancer. ( 25486104 )
2015
10
Comorbidity is an independent prognostic factor in women with uterine corpus cancer: a nationwide cohort study. ( 24443826 )
2014
11
State-level uterine corpus cancer incidence rates corrected for hysterectomy prevalence, 2004 to 2008. ( 23125334 )
2013
12
Efficacy of para-aortic lymphadenectomy in early-stage endometrioid uterine corpus cancer. ( 21136177 )
2011
13
Comparative performance of the 2009 International Federation of Gynecology and Obstetrics' staging system for uterine corpus cancer. ( 21508766 )
2011
14
Comparative Performance of the 2009 International Federation of Gynecology and Obstetrics' Staging System for Uterine Corpus Cancer. ( 21705925 )
2011
15
Comparison of second cancer risks from brachytherapy and external beam therapy after uterine corpus cancer. ( 20142245 )
2010
16
Current status in the management of uterine corpus cancer in Korea. ( 20922137 )
2010
17
Evaluation of FDG-PET for detecting lymph node metastasis in uterine corpus cancer. ( 20944170 )
2010
18
Comparative performance of the 2009 international Federation of gynecology and obstetrics' staging system for uterine corpus cancer. ( 20966700 )
2010
19
Positron emission tomography with the glucose analog [F]-fluoro-2-deoxy-D-glucose for evaluating pelvic lymph node metastasis in uterine corpus cancer: comparison with CT and MRI findings. ( 19215544 )
2009
20
Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer. ( 18064567 )
2008
21
Comparison of the validity of magnetic resonance imaging and positron emission tomography/computed tomography in the preoperative evaluation of patients with uterine corpus cancer. ( 18201753 )
2008
22
FDG PET for the assessment of myometrial infiltration in clinical stage I uterine corpus cancer. ( 16710101 )
2006
23
The use of adjuvant radiation therapy in patients with intermediate-risk Stages IC and II uterine corpus cancer: a patient care evaluation study from the American College of Surgeons National Cancer Data Base. ( 16198401 )
2005
24
Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. ( 15581961 )
2004
25
Ethnic differences in uterine corpus cancer incidence and mortality in New Mexico's American Indians, hispanics and non-Hispanic whites. ( 9169158 )
1997
26
Identification of TP53 gene mutations in uterine corpus cancer with short follow-up. ( 9441778 )
1997
27
Correlation of C-myc and HER-2/neu amplification and expression with histopathologic variables in uterine corpus cancer. ( 7977518 )
1994
28
Estriol binding in uterine corpus cancer and in normal uterine tissues. ( 1869022 )
1991
29
A cohort analysis of breast cancer, uterine corpus cancer, and childbearing pattern in Norwegian women. ( 2273359 )
1990
30
Height and weight in relation to uterine corpus cancer morbidity and mortality. A follow-up study of 570,000 women in Norway. ( 2384266 )
1990

Variations for Uterine Corpus Cancer

Copy number variations for Uterine Corpus Cancer from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 162862 22 22706138 22714284 Decreasing copy numb er GSTT1 Corpus uteri cancer

Expression for Uterine Corpus Cancer

Search GEO for disease gene expression data for Uterine Corpus Cancer.

Pathways for Uterine Corpus Cancer

Pathways related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

(show all 45)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.39 BRCA1 ERBB2 MYC PIK3CA PPP2R1A TP53
2
Show member pathways
12.73 ERBB2 MYC PIK3CA TP53
3 12.7 ERBB2 MYC PIK3CA TP53
4
Show member pathways
12.68 BRCA1 ERBB2 MYC PIK3CA PPP2R1A TP53
5
Show member pathways
12.58 ERBB2 PIK3CA PPP2R1A TP53
6
Show member pathways
12.56 BRCA1 ERBB2 PIK3CA TP53
7
Show member pathways
12.56 BRCA1 FBXW7 MYC TP53
8
Show member pathways
12.56 BRCA1 ERBB2 MYC PIK3CA TP53
9
Show member pathways
12.44 ERBB2 MYC PIK3CA TP53
10
Show member pathways
12.42 ERBB2 MYC PIK3CA TP53
11
Show member pathways
12.38 ERBB2 MYC PIK3CA TP53
12 12.35 BRCA1 PPP2R1A S100A6 TP53
13 12.13 ERBB2 MYC PIK3CA TP53
14 12.13 BRCA1 ERBB2 MYC PIK3CA TP53
15
Show member pathways
12.09 BRCA1 FBXW7 MYC
16 12.05 MYC PIK3CA TP53
17
Show member pathways
12.03 ERBB2 MYC PIK3CA TP53
18 12.02 BRCA1 MYC TP53
19
Show member pathways
12.01 ERBB2 MYC PIK3CA
20
Show member pathways
11.93 BRCA1 MYC PIK3CA PPP2R1A
21 11.91 ERBB2 MYC PIK3CA TP53
22
Show member pathways
11.9 ERBB2 PIK3CA TP53
23 11.87 PIK3CA PPP2R1A TP53
24 11.86 MYC PIK3CA TP53
25 11.78 MYC PIK3CA PPP2R1A
26 11.73 MYC PIK3CA TP53
27 11.68 ERBB2 MYC PIK3CA TP53
28 11.6 ERBB2 MYC TP53
29 11.5 BRCA1 ERBB2 MYC
30
Show member pathways
11.49 ERBB2 MYC PIK3CA
31 11.39 BRCA1 MYC TP53
32 11.32 BRCA1 MYC TP53
33 11.32 BRCA1 ERBB2 PIK3CA TP53
34 11.25 BRCA1 MYC TP53
35 11.2 BRCA1 TP53
36 11.18 ERBB2 PIK3CA
37 11.18 BRCA1 TP53
38 11.15 BRCA1 TP53
39 11.13 MYC TP53
40 11.1 MYC S100A6 TP53
41 11.07 ERBB2 MYC PIK3CA TP53
42 11 MYC TP53
43
Show member pathways
11 MYC TP53
44 10.92 BRCA1 TP53
45 10.92 BRCA1 ERBB2 FBXW7 MYC PIK3CA TP53

GO Terms for Uterine Corpus Cancer

Biological processes related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of fibroblast proliferation GO:0048147 9.4 MYC TP53
2 ERBB2 signaling pathway GO:0038128 9.37 ERBB2 PIK3CA
3 response to gamma radiation GO:0010332 9.32 MYC TP53
4 positive regulation of cell cycle arrest GO:0071158 9.26 BRCA1 TP53
5 positive regulation of gene expression GO:0010628 9.26 BRCA1 ERBB2 MYC TP53
6 vasculature development GO:0001944 9.16 FBXW7 PIK3CA
7 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.62 BRCA1 TP53

Molecular functions related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 8.92 ERBB2 MYC PPP2R1A TP53

Sources for Uterine Corpus Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....